Results 271 to 280 of about 22,239 (295)

Novel compounds as dipeptidyl peptidase IV (dpp iv) inhibitors

2009
The present invention is related to novel compounds of the general formula (A), their tautomeric forms, their stereoisomers, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, methods of making of the above compounds, and their use as Dipeptidyl Peptidase-IV (DPP-IV) Inhibitors, which are useful in the treatment or ...
Arora, Sudershan, Sinha, Neelima, Nair, Prathap, Chakka, Sai Kumar, Hajare, Anil, Reddy, Azmi, Patil, Pravin, Sayyed, Majid, Kamboj, Rajender Kumar, Swamy, K.H. Sreedhara, Goel, Rajan   +10 more
openaire  

Safety of dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials

Therapeutic Advances in Drug Safety, 2022
Stefanie Buhn, Alina Weise, Nina-Kristin Mann   +2 more
exaly  

Synthesis of a Dipeptidyl Peptidase IV Inhibitor

Synfacts, 2010
openaire   +1 more source

Hemorphins: substrates and/or inhibitors of dipeptidyl peptidase IV

Biochimie, 2004
Cohen, M., Fruitier-Arnaudin, I., Piot, M   +2 more
openaire   +2 more sources

Effect of dipeptidyl peptidase-4 inhibitors on heart failure: A meta-analysis of randomized clinical trials

International Journal of Cardiology, 2016
P Dilokthornsakul, Surakit Nathisuwan, Arintaya Phrommintikul   +2 more
exaly  

Dipeptidyl peptidase IV inhibitors

2016
openaire   +1 more source

Safety of dipeptidyl peptidase 4 inhibitors: a perspective review

Therapeutic Advances in Drug Safety, 2014
Thomas Karagiannis, Apostolos Tsapas
exaly  

Gastrointestinal Adverse Events of Dipeptidyl Peptidase 4 Inhibitors in Type 2 Diabetes: A Systematic Review and Network Meta-analysis

Clinical Therapeutics, 2017
Sanbao Chai, Yang Xu, Zhirong Yang
exaly  

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis

Annals of Pharmacotherapy, 2012
Haesuk Park, Chanhyun Park, Karen L Rascati   +2 more
exaly  

Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?

Diabetes and Vascular Disease Research, 2019
Nordin M J Hanssen
exaly